November 9, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2612463

ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels.

Listen to this summary

This phase 2b randomized, placebo-controlled trial (TYDAL-TIMI 78, part A) asked whether inhibiting ANGPTL4 with the monoclonal antibody MAR001 lowers fasting triglyceride levels in adults with elevated triglycerides. Among 235 participants treated subcutaneously every 4 weeks for 24 weeks, MAR001 at 300, 450, or 900 mg reduced fasting triglycerides at week 12 by 39.1, 40.5, and 45.3 percentage points more than placebo (all P<0.001). The adverse event rate was lower in the MAR001 group (69%) than in the placebo group (78%).

Michelle L O'Donoghue, Rebecca A Juliano, B Alexander Yi, Bernard Chung, Matilda Hughes, Daniel Gaudet, Harvey White, Gerald F Watts, Julia Kuder, KyungAh Im, Yining Ye, Ethan J Weiss, Joshua Lehrer-Graiwer, Marc S Sabatine

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play